CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 8, 2006--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), today announced that the fifty-second and final patient has been enrolled in the Company's Phase IIa study of its thrombus-imaging agent, EP-2104R. The study included six cohorts of patients, all of which enrolled at least eight patients. The final cohort, consisting of patients with a potential clot in the left or right atrium, enrolled its eighth and final patient on March 7, 2006. The announcement was made by Michael J. Astrue, EPIX Interim CEO, during a Company presentation at the Cowen & Co. 26th Annual Health Care Conference being held in Boston, Massachusetts.
